ACTH Treatment of APOL1- Associated Nephropathy

Withdrawn before enrolling · Not applicable

Conditions studied: Kidney Disease

In brief

The purpose of this research study is to determine if the study drug H.C. Acthar gel slows the progression of your kidney disease. This drug is a steroid-based medicine with fewer side effects than other steroids used for treatment of kidney diseases similar to APOL1 nephropathy.

Key facts

Study ID

NCT02006849

Run by

Wake Forest University Health Sciences

People needed

0

Starts

2014-01-01

Expected to finish

2019-01-01

Last updated by the study team

2017-11-07

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Non-diabetic African-American with two APOL1-risk genotypes
• Age ≥21 years
• BMI < 40 kg/m2
• Hemoglobin A1c <6.5%
• eGFR ≥30 ml/min/1.73m2
• Historical urine protein: creatinine ratio ≥ 1.0 g/g
• Strong clinical suspicion of APOL1-associated nephropathy or history of biopsy proven focal segmental glomerulosclerosis (FSGS) or focal global glomerulosclerosis (FGGS)
• Women of childbearing potential: negative serum pregnancy test at Screening and agreement to follow a medically acceptable form of contraception for the duration of Acthar administration and 4 weeks thereafter

You may not qualify if…

• Diagnosis of diabetes mellitus and/or on pharmacologic treatment for diabetes
• Medical condition that could cause secondary FSGS
• History of sensitivity to steroids (psychosis, steroid-induced diabetes)
• Chronic systemic corticosteroid use (Prednisone or equivalent systemic steroid taken for more than 4 consecutive weeks within 6 months prior to screening). Intra-articular, inhaled, and topical steroids are not exclusion criteria.
• Contraindication to Acthar per package insert: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery (within previous 6 months), history of or the presence of peptic ulcer (within 6 months prior to Screening), adrenal insufficiency or hyperfunction.
• Acute glaucoma diagnosed ≤3 months prior to Screening
• Biopsy proven glomerular disease other than FSGS or FGGS
• Live or live attenuated vaccine received within 1 month prior to screening, or planned administration once enrolled in the study
• Uncontrolled hypertension (HTN) (≥ 180/110 mmHg) and frequent admissions (≥1 admission per 6 months interval) for hypertensive urgency or hypertensive emergency
• Unstable cardiovascular disease: history of congestive heart failure (NYHA Functional Class III-IV); history of dilated cardiomyopathy with ejection fraction < 40%; any of the following events within 3 months of screening: unstable angina, myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angioplasty, transient ischemic attack or cerebrovascular accident, unstable arrhythmia
• Uncontrolled volume overload: history of moderate or severe peripheral edema; on loop diuretics ≥ 120 mg daily of furosemide or ≥ 3.0 mg daily of bumetanide or ≥ 150 mg daily of ethacrynic acid or ≥ 60 mg daily of torsemide;
• History of secondary hypertension (i.e., renal artery stenosis, primary aldosteronism or pheochromocytoma)
• Significant comorbidities (e.g., advanced malignancy, advanced liver disease) with a life expectancy of less than 1 year
• Subject is expected to initiate dialysis within 6 months
• Previous treatment on a drug being investigated for the treatment of FSGS
• Known diagnosis of Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C
• Known history of a primary immunodeficiency or an underlying condition such as splenectomy that predisposes the subject to infections
• Systemic hematologic disease (e.g., hematologic malignancy, sickle cell anemia, myelodysplastic syndrome)
• Current malignancy or history of malignancy within 5 years of screening, with the exception of non-melanoma skin cancers and cervical intraepithelial neoplasia
• Treatment for any malignancy (e.g., radiation, chemotherapy, hormone therapy, or biologics) within 5 years of screening, with the exception of locally excised non-melanoma skin cancer or cervical intraepithelial neoplasia
• Pregnant or breast feeding, or might become pregnant during the study or within 4 weeks after the end of treatment
• Female of reproductive potential not willing to use highly effective methods of birth control during treatment and for 4 weeks after the end of treatment
• Currently receiving systemic antibiotics for treatment of an active infection; or history of frequent infections (more than one event per 6 months)
• History of any organ transplant
• Bipolar disorder, or Major Depressive Disorder characterized by severe depression requiring hospitalization, or history of suicidal ideation/attempts

Where it is running

• Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.